190 related articles for article (PubMed ID: 28627741)
1. Proteomics approach to identify novel metastatic bone markers from the secretome of PC-3 prostate cancer cells.
Sung E; Kwon OK; Lee JM; Lee S
Electrophoresis; 2017 Oct; 38(20):2638-2645. PubMed ID: 28627741
[TBL] [Abstract][Full Text] [Related]
2. Global and Targeted Proteomics of Prostate Cancer Cell Secretome: Combination of 2-Dimensional Image-Converted Analysis of Liquid Chromatography and Mass Spectrometry and In Silico Selection Selected Reaction Monitoring Analysis.
Nurdin A; Hoshi Y; Yoneyama T; Miyauchi E; Tachikawa M; Watanabe M; Terasaki T
J Pharm Sci; 2016 Nov; 105(11):3440-3452. PubMed ID: 27665127
[TBL] [Abstract][Full Text] [Related]
3. Comparative Secretome Profiling and Mutant Protein Identification in Metastatic Prostate Cancer Cells by Quantitative Mass Spectrometry-based Proteomics.
Kwon OK; Jeon JM; Sung E; Na AY; Kim SJ; Lee S
Cancer Genomics Proteomics; 2018; 15(4):279-290. PubMed ID: 29976633
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
Sardana G; Jung K; Stephan C; Diamandis EP
J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
[TBL] [Abstract][Full Text] [Related]
5. Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer.
Mbeunkui F; Metge BJ; Shevde LA; Pannell LK
J Proteome Res; 2007 Aug; 6(8):2993-3002. PubMed ID: 17608509
[TBL] [Abstract][Full Text] [Related]
6. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context.
Schaaij-Visser TB; de Wit M; Lam SW; Jiménez CR
Biochim Biophys Acta; 2013 Nov; 1834(11):2242-58. PubMed ID: 23376433
[TBL] [Abstract][Full Text] [Related]
7. Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells.
Qiu JX; Zhou ZW; He ZX; Zhao RJ; Zhang X; Yang L; Zhou SF; Mao ZF
Drug Des Devel Ther; 2015; 9():349-417. PubMed ID: 25609920
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
[TBL] [Abstract][Full Text] [Related]
9. Comparative Proteomics Uncovers Correlated Signaling Network and Potential Biomarkers for Progression of Prostate Cancer.
Ai J; Lu Y; Wei Q; Li H
Cell Physiol Biochem; 2017; 41(1):1-9. PubMed ID: 28437789
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer.
Hu R; Huffman KE; Chu M; Zhang Y; Minna JD; Yu Y
J Proteome Res; 2016 Feb; 15(2):477-86. PubMed ID: 26736068
[TBL] [Abstract][Full Text] [Related]
11. Quantitative proteomic analysis exploring progression of colorectal cancer: Modulation of the serpin family.
Peltier J; Roperch JP; Audebert S; Borg JP; Camoin L
J Proteomics; 2016 Oct; 148():139-48. PubMed ID: 27492143
[TBL] [Abstract][Full Text] [Related]
12. Comparative membrane proteomics analyses of breast cancer cell lines to understand the molecular mechanism of breast cancer brain metastasis.
Peng W; Zhang Y; Zhu R; Mechref Y
Electrophoresis; 2017 Sep; 38(17):2124-2134. PubMed ID: 28523741
[TBL] [Abstract][Full Text] [Related]
13. Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium.
Sardana G; Marshall J; Diamandis EP
Clin Chem; 2007 Mar; 53(3):429-37. PubMed ID: 17259234
[TBL] [Abstract][Full Text] [Related]
14. Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis.
Jin L; Zhang Y; Li H; Yao L; Fu D; Yao X; Xu LX; Hu X; Hu G
Cell Res; 2012 Sep; 22(9):1356-73. PubMed ID: 22688893
[TBL] [Abstract][Full Text] [Related]
15. The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications.
Iglesias-Gato D; Thysell E; Tyanova S; Crnalic S; Santos A; Lima TS; Geiger T; Cox J; Widmark A; Bergh A; Mann M; Flores-Morales A; Wikström P
Clin Cancer Res; 2018 Nov; 24(21):5433-5444. PubMed ID: 30042207
[No Abstract] [Full Text] [Related]
16. iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.
Rehman I; Evans CA; Glen A; Cross SS; Eaton CL; Down J; Pesce G; Phillips JT; Yen OS; Thalmann GN; Wright PC; Hamdy FC
PLoS One; 2012; 7(2):e30885. PubMed ID: 22355332
[TBL] [Abstract][Full Text] [Related]
17. Global secretome analysis identifies novel mediators of bone metastasis.
Blanco MA; LeRoy G; Khan Z; Alečković M; Zee BM; Garcia BA; Kang Y
Cell Res; 2012 Sep; 22(9):1339-55. PubMed ID: 22688892
[TBL] [Abstract][Full Text] [Related]
18. Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormone-related protein.
Yan Z; Jin S; Wei Z; Huilian H; Zhanhai Y; Yue T; Juan L; Jing L; Libo Y; Xu L
Biochim Biophys Acta; 2014 Sep; 1842(9):1350-63. PubMed ID: 24787381
[TBL] [Abstract][Full Text] [Related]
19. [Serum proteomic study of prostate cancer with bone metastasis].
Zhang XM; Shen Y; Xianyu ZQ
Zhonghua Nan Ke Xue; 2010 Aug; 16(8):721-5. PubMed ID: 21090348
[TBL] [Abstract][Full Text] [Related]
20. Quantitative proteomic study of human prostate cancer cells with different metastatic potentials.
Li Q; Li Y; Wang Y; Cui Z; Gong L; Qu Z; Zhong Y; Zhou J; Zhou Y; Gao Y; Li Y
Int J Oncol; 2016 Apr; 48(4):1437-46. PubMed ID: 26846621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
